TELA Bio, a surgical reconstruction company focused on developing tissue reinforcement materials, has announced the upcoming release of its third-quarter 2025 financial results. Investors and interested parties can anticipate the announcement on Thursday, November 13, 2025. The news came directly from the company headquarters in Malvern, Pennsylvania.

Following the release of the financial data, TELA Bio will host a conference call and live webcast to discuss the results in greater detail. While specific details regarding the time of the call were not immediately available, the company is expected to announce that information shortly. This call will offer an opportunity for analysts, investors, and members of the media to gain a deeper understanding of the company's performance during the third quarter.

TELA Bio's financial results are eagerly anticipated, particularly as the company continues to navigate the competitive landscape of surgical reconstruction. The third-quarter report will provide valuable insights into the company's revenue, profitability, and overall growth trajectory. Key areas of focus are likely to include sales performance of its OviTex Reinforced Tissue Matrix, a product line used in a variety of surgical procedures, including hernia repair and abdominal wall reconstruction.

Investors will also be keen to hear updates on TELA Bio's strategic initiatives, including any progress in expanding its market reach, developing new product offerings, and managing its operating expenses. The conference call is expected to feature commentary from key members of TELA Bio's leadership team, who will likely provide context for the financial results and outline the company's outlook for the remainder of 2025 and beyond. The webcast will offer a convenient way for those unable to participate in the live call to follow along with the presentation and Q&A session. It is advisable to check the company's investor relations website for specific details regarding the call's timing and access information.